XSHE
300878
Market cap622mUSD
Oct 09, Last price
29.90CNY
1D
1.87%
1Q
-9.42%
IPO
-46.02%
Name
Zhejiang Wecome Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Wecome Pharmaceutical Company Limited primarily focuses on the innovation, manufacturing, and distribution of pharmaceutical products. Beyond its core medicinal offerings, the company also provides a range of healthcare items, over-the-counter (OTC) medications, and traditional Chinese remedies. These products are available in numerous formats, including hard and soft capsules, tablets, granules, and pills, among other dosage forms. Established in 2000, the firm, previously known as Zhejiang Weikang Pharmaceutical Co., Ltd., is headquartered in Lishui, China.
Key people
Jing Wang
Chief Financial Officer · since 2021
Dexiong Dai
Deputy General Manager · since 2015
Jingwei Ding
Deputy General Manager · since 2021
Dong Liu
Deputy General Manager · since 2024
Jianming Wu
Deputy General Manager, Director · since 2021
Zhangqi Zhang
Deputy General Manager · since 2022
Jie Hua
Staff Elected Director · since 2025
Xiaoxia Kong
Deputy General Manager, Director · since 2024
Ting Zhu
Director · since 2025
Lan Hao
Independent Director · since 2021
Independent Director · since 2021
Jinxia Wang
Independent Director · since 2021
Bin Wu
Independent Director · since 2022
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||